Lanzapine

Quick links to important sections

Lanzapine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanzapine

What is Lanzapine? A Verified Overview of its Identity

Lanzapine is the trade name for a medicine whose active compound is Olanzapine (INN), a powerful psychotropic agent used for managing severe psychiatric conditions. It is defined by its specific chemical structure, which is a thienobenzodiazepine derivative.

Property Description
Active ingredient Olanzapine
Form Tablet, Orally Disintegrating Tablet (ODT), Powder for Solution for Injection
Pharmacological class Second-Generation Antipsychotic (Atypical Antipsychotic)
Common purpose To stabilize thought, perception, and mood regulation
Origin Synthetic, Thienobenzodiazepine derivative

What Type of Medicine is Lanzapine?

Lanzapine is classified as a second-generation antipsychotic, a category clinically recognized for its role in modulating the central nervous system. This group of medications is commonly referred to as atypical antipsychotics. The drug is a prescription-only (Rx) medication, underscoring its use in controlled settings for complex conditions. As a synthetic compound, Olanzapine is chemically manufactured to target specific receptor sites within the brain.

Lanzapine's Forms and Composition

The active ingredient, Olanzapine, is consistently a single-ingredient product across its major formulations. The most common forms are the standard oral tablet and the orally disintegrating tablet (ODT). For acute or specialized care, it is also manufactured as a powder for solution for injection for short-term intramuscular administration. These multiple pharmaceutical preparations provide flexibility for sustained maintenance or immediate intervention.

What is the General Purpose of Lanzapine?

The general purpose of Lanzapine is to correct imbalances in the brain's signaling system through neurotransmitter rebalancing. The core mechanism principle involves regulating the activity of key chemical messengers, acting as a selective monoaminergic antagonist to certain receptors for dopamine and serotonin. By modulating the effects of these brain chemicals, the medicine helps to stabilize disorganized thought processes, reduce severe perceptual disturbances, and normalize mood regulation, which is the foundational goal of its therapeutic application.

Regulatory References

  1. Olanzapine - StatPearls - NCBI Bookshelf

What side effects are possible with Lanzapine?

Possible Side Effects and Safety Information

Lanzapine’s safety profile, as documented in official regulatory sources, includes risks categorized by frequency, system-organ class, and patient population.

Serious Adverse Reactions and Restrictions

Official documents include a Boxed Warning regarding the increased risk of death, stroke, or transient ischemic attack (TIA) when Lanzapine is used to treat elderly patients with dementia-related psychosis; use in this population is contraindicated. Other serious adverse reactions that require immediate attention include Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Metabolic and Systemic Safety Concerns

The most commonly reported adverse reactions often involve metabolic changes. These include weight gain (very common), the development or exacerbation of diabetes mellitus/hyperglycemia (sometimes severe, leading to ketoacidosis or coma), and dyslipidemia (elevated cholesterol and triglyceride levels).

Very Common side effects (ge 1/10 treated patients) also include somnolence (drowsiness) and elevated prolactin levels. Common side effects (ge 1/100 to < 1/10) include orthostatic hypotension (dizziness upon standing), constipation, increased appetite, and movement disorders such as akathisia and parkinsonism.

Monitoring and Population-Specific Safety

Official guidelines require the monitoring of weight, fasting blood glucose, and lipid profiles at the start of treatment and periodically thereafter. Certain patient populations have distinct risk patterns: adolescent patients have shown a greater magnitude of weight gain, lipid alterations, and prolactin elevations compared to adults. Caution is advised in patients with a history of seizures or known cardiovascular, cerebrovascular, or hypotensive conditions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope

  • Documented overdose presentations: The official label documents overdose presentations including central nervous system depression, which can range from somnolence to coma, alongside tachycardia, hypotension, extrapyramidal effects, and anticholinergic signs such as miosis and blurred vision. Physiological systems affected include the Central Nervous System, Cardiovascular System, and Motor Function.
  • Population-specific overdose notes: Pediatric overdoses are officially noted to be associated with more significant adverse effects and require more active intervention than in adults.
  • Emergency-response statements: In the event of suspected overdose, immediate medical attention must be sought. Management is focused solely on symptomatic and supportive treatment; no specific antidote is known. Essential procedures include establishing and maintaining a patent airway and ensuring adequate oxygenation and ventilation.

Overdose classifications (high-level)

  • Severity classification: Severe manifestations include respiratory depression, delirium, and the risk of death attributed to probable cardiac toxicity. Cases of extreme hyperglycemia, ketoacidosis, or hyperosmolar coma have also been reported.
  • When immediate medical help is required: Close medical supervision and monitoring must be instituted until all signs and symptoms have resolved. Patients receiving the injectable formulation require mandatory observation for a minimum of two hours following administration in a healthcare facility with access to emergency services.

Connection to the overall overdose profile

The regulatory profile defines overdose by listing severe neurological and cardiovascular manifestations that necessitate urgent care, as these signs are linked to life-threatening outcomes. The mandated response centers on symptomatic and supportive treatment under continuous medical supervision, exactly as stated in official labeling, due to the confirmed absence of a specific antidote.

Therapeutic Uses of Lanzapine

What Lanzapine Treats: Main Uses and Benefits

Lanzapine (Olanzapine) is generally used across severe psychiatric conditions to support the management of intense symptomatic discomfort. The medication is commonly used to help treat conditions characterized by periods of heightened symptoms, including Schizophrenia and Bipolar I Disorder (covering manic, mixed, and depressive episodes, and maintenance therapy).

It is relevant in clinical settings where symptoms lead to noticeable functional strain, such as in the acute stabilization of psychosis or the control of agitation. Lanzapine helps to moderate distressing manifestations like hallucinations, delusions, and racing thoughts, which interfere with daily stability.

“Lanzapine provides support that helps ease the overall symptom burden during difficult episodes, and supports the patient during difficult episodes by easing distress, especially when managing recurrent conditions.”

Symptom-Focused Relief

The medication is applied to address groups of symptoms that may become intense or disruptive. For psychotic symptoms, it supports the management of perceptual challenges; for mood symptoms, it helps ease the distress associated with manic episodes. The overall benefit contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Acute Agitation Lanzapine is commonly used to help with short-term symptomatic assistance during phases when heightened symptoms become temporarily overwhelming.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Lanzapine?

Eligibility for Lanzapine (Olanzapine) is defined by official regulatory labeling, outlining specific populations who are approved users, those who are strictly prohibited, and those who require conditional use. This information is based on governmental prescribing documents.


Prohibited Use (Contraindications)

Lanzapine is formally contraindicated and must not be used in the following populations:

  • Elderly patients with dementia-related psychosis, due to an increased risk of mortality.
  • Patients with a known hypersensitivity to Olanzapine or any component of the product.
  • Patients with a known risk of narrow-angle glaucoma.

Age-Group and Condition-Based Eligibility

The medicine is approved for adults (generally ge 18) with Schizophrenia and Bipolar I Disorder. It is also approved for adolescents (ages 13-17) for specific uses in the US and Canada, but is generally not recommended for children and adolescents under 18 in Europe due to insufficient data.

  • Physiological States: Use is not recommended during breastfeeding as the drug is secreted into breast milk. Use during the third trimester of pregnancy requires careful consideration due to the risk of withdrawal symptoms in the newborn.
  • Conditional Use: Caution is required in patients with a history of seizures, cardiac conditions, or hepatic impairment.

What should I know about interactions with other medicines?

Lanzapine Interactions with Other Medicines and Products

Official regulatory documents define Lanzapine's (Olanzapine) interaction profile by its primary metabolic pathway and potential for additive clinical effects.

Documented Interaction Mechanisms

Lanzapine is primarily metabolized by the CYP1A2 enzyme, which is the basis for several official pharmacokinetic interactions. Fluvoxamine, a potent CYP1A2 inhibitor, is documented to significantly increase Lanzapine plasma concentrations and reduce its clearance by 50% to 60%. Conversely, CYP1A2 inducers like Rifampin and smoking increase Lanzapine clearance, potentially lowering its concentration.

Pharmacodynamic interactions arise from Lanzapine's effects on the central nervous system (CNS) and blood pressure. Co-administration with Centrally Acting Agents (such as opiates) may lead to additive CNS depression. Similarly, concurrent use with antihypertensive agents may lead to enhanced hypotensive effects.

Interaction-Related Restrictions and Constraints

Classification Interacting Substance Constraint and Context
Prohibited Combination Parenteral Benzodiazepines (e.g., IV Diazepam) Concomitant administration with intramuscular (IM) Olanzapine is not recommended or is formally contraindicated due to the risk of excessive sedation and cardiorespiratory depression. A specific timing separation (e.g., at least 60 minutes) is advised between IM Olanzapine and parenteral benzodiazepines.
Exposure Reduction Activated Charcoal Reduces Lanzapine exposure/bioavailability by 50% to 60% due to binding in the gastrointestinal tract.
Lifestyle Interaction Alcohol Enhances CNS depressant effects and is contraindicated with IM Olanzapine injection.

Regulatory agencies also note that Lanzapine clearance is lower in certain populations, including females, the elderly, and non-smokers, which affects the resulting exposure when metabolic interacting agents are co-administered.

Mechanism of Action

How Lanzapine Works — Mechanism of Action

Antagonism of Dopamine and Serotonin Receptors

Lanzapine’s core biological mechanism is its high-affinity blockade (antagonism) of multiple central nervous system receptors, predominantly the dopamine D2 and serotonin 5-HT2 A receptors. This action affects systems where these transmitters dominate, reducing the impact of excessive signaling in key brain pathways, contributing to an overall modulation of neural activity.

Modulation of Intracellular Signaling Cascades

Beyond immediate receptor blockade, Lanzapine engages mechanisms that influence feedback regulation and signal transduction within neurons, modifying early molecular steps in pathways like the cAMP cascade. This action modifies the effect of excessive mediator activity, influencing the physiological adjustments related to neuronal function and plasticity.

Systemic Effects from Broad Receptor Antagonism

The drug's mechanism extends to non-dopaminergic receptors, including antagonism of histamine H1 and muscarinic cholinergic receptors. This broad receptor antagonism leads to predictable physiological effects such as sedation ( H1 blockade), anticholinergic responses (muscarinic blockade), and modulation of metabolic systems, which collectively influence the spectrum of physiological consequences.

Dosage and Administration Information

How to Use Lanzapine

Lanzapine (Olanzapine) is administered through distinct routes that correspond to its use in acute stabilization or long-term management. The primary forms are the oral tablet and the orally disintegrating tablet (ODT) for daily dosing, and two types of intramuscular (IM) injection for professional administration.


Dosing and Frequency Patterns

The standard oral regimen is taken once daily. The typical adult starting dose is between 5 mg and 15 mg, with the maximum daily oral dose set at 20 mg. Adjustments to the dose, if deemed necessary, are officially recommended to occur in increments of 5 mg at intervals of no less than one week. The medicine can be taken with or without food.

Specialized Administration

Use of the injectable form is specialized based on the preparation. The short-acting IM injection is used for acute circumstances, allowing up to 3 doses in a 24-hour period, not to exceed 30 mg. The long-acting injection is administered on a fixed schedule of every two or four weeks.

Procedural and Population Rules

For the orally disintegrating tablet, patients are instructed to handle the medication with dry hands before placing it on the tongue, where it dissolves rapidly. For the long-acting IM form, a critical procedural requirement is mandatory: patients must be kept under observation at the healthcare facility for a minimum of three hours after the injection. Official guidelines also recommend considering a lower oral starting dose of 5 mg per day for certain groups, including older adults (65 years and older) and those with hepatic impairment.

Recent Clinical Evidence

Lanzapine: Recent Clinical Evidence

This section describes the types of clinical studies that have been conducted on Lanzapine (Olanzapine) and what research has examined for its approved uses. The findings presented here reflect group patterns observed in research and are not individual predictions.

Evidence for Use in Schizophrenia

Research for conditions characterized by fluctuating or episodic manifestations like schizophrenia involves short-term, randomized controlled trials (RCTs) and long-term observational studies. Scientists used these in research exploring how symptoms change over time, comparing Lanzapine to placebo or other medications. Long-term studies monitored patterns in symptom evolution and recurrence over many months, but information on functional outcomes, such as social functioning, is not fully established. Follow-up durations were limited for many assessments.

Evidence for Use in Bipolar I Disorder

Lanzapine was studied for conditions characterized by fluctuating manifestations, including acute manic or mixed episodes. Research involved short-term RCTs and longer maintenance trials where the drug was evaluated in patients who had achieved a stable phase, with research exploring the frequency of recurrence. Studies monitored symptom severity over periods typically spanning three to four weeks in acute-phase research. However, there is limited information regarding general patient-reported quality of life or the long-term observation of metabolic changes.

Research on Acute Agitation and Special Populations

Research was also studied in research exploring temporary physiological imbalance, such as severe agitation, often using the injectable form. These ultra-short-term trials examined time until initial patterns of symptom control were observed. Separately, Lanzapine was evaluated in adolescents (aged 13 and older) where research primarily examined outcomes related to symptom intensity or variability. Data for other groups, such as older adults, remain insufficient, and long-term effects are not fully established for repeated acute use or in these special populations.

Key Studies & References

  1. Olanzapine - StatPearls (FDA-approved Indications, Special Populations, Acute Agitation)
  2. Clinical and functional outcomes for patients with schizophrenia treated with olanzapine (Long-term Functional Data)

Frequently Asked Questions (FAQ)

Common questions about Lanzapine (FAQ)


Q: How long does it usually take for Lanzapine to start having an effect?

A: Official information indicates that the medicine typically reaches its highest level in the blood about 5 to 8 hours after an oral dose. In research for its main approved uses, some initial patterns of improvement may be observed within 1 to 2 weeks, with patterns in research indicating the time frame for a full response may extend up to 6 weeks.


Q: What happens if I forget to take a dose of Lanzapine?

A: Regulatory documents describe the procedure for a missed dose: generally, it is advised to take the missed dose as soon as it is remembered. If it is nearly time for the next scheduled dose, regulatory guidance describes skipping the missed dose and resuming the regular schedule. Official guidance strictly advises that two doses should not be taken at the same time.


Q: How quickly does the effect of Lanzapine wear off after a dose?

A: The medicine's half-life, a measure of the time it takes for half of the drug to be eliminated from the body, typically ranges from 21 to 54 hours in adults. This means the substance remains present in the body for an extended period after each dose.


Q: What are the long-term effects of taking Lanzapine?

A: Long-term use requires monitoring for known metabolic changes according to regulatory documentation. These include weight gain and alterations in fasting blood sugar and lipid profiles (cholesterol and triglycerides). Official documentation outlines the requirement for periodic professional assessment for individuals using the medicine for maintenance treatment.


Q: Does Lanzapine change your personality or mood in a major way?

A: Lanzapine is officially described as a psychotropic agent intended to stabilize thought, perception, and mood regulation. Its mechanism involves modulating chemical messengers in the brain. The medicine is intended to target and support the stabilization of thought, perception, and mood regulation.


Q: Are there any specific foods or drinks, like grapefruit juice, that interact with Lanzapine?

A: Grapefruit or grapefruit juice are not listed as documented food interactions in official drug information. The medicine can officially be taken with or without food, as its effectiveness is generally not tied to mealtimes.


Q: Do you have to take Lanzapine forever once you start taking it?

A: Official guidelines indicate that the necessary duration of treatment depends on the specific condition being managed. For conditions requiring long-term management, regulatory guidelines describe treatment duration that can extend for a substantial period after stabilization. The exact duration is determined by the specific condition and individual clinical pattern.


Q: Can Lanzapine cause insomnia or other sleep problems?

A: While drowsiness (somnolence) is listed as a very common side effect, official safety information also reports insomnia (difficulty sleeping) and general sleep disorder as potential adverse reactions in some patients.


Q: Is there any research looking at how Lanzapine affects children or teenagers?

A: Research has been conducted on adolescents aged 13–17 to examine symptom intensity outcomes for approved uses. This research documented that this group may experience a greater magnitude of weight gain and changes to lipid and prolactin levels compared to adults.


Q: What should I do if the side effects of Lanzapine feel too strong?

A: Regulatory documents contain a specific warning that sudden discontinuation of the medicine can cause serious side effects. If side effects are concerning, official guidance is to consult with a healthcare professional to determine how to safely adjust or discontinue the medicine.


Q: Is there evidence that Lanzapine is used in emergency situations?

A: Yes, an injectable form of Lanzapine is specifically approved for professional use in acute circumstances. This formulation is used for the rapid control of severe agitation associated with its approved conditions.


Q: What are the specific signs that Lanzapine is starting to work?

A: Official documents describe the intended therapeutic effect as promoting clearer thoughts, stable mood, and reducing agitation or intense fears. Research patterns indicate that some initial changes may be noted within the first two weeks of treatment.


Q: Can Lanzapine cause problems with sexual function?

A: Regulatory safety information lists decreased sexual ability (or reduced libido) as a potential adverse reaction. This is one of the possible side effects documented in the official product information.


Q: Is there any research on stopping Lanzapine after long-term use?

A: Official regulatory warnings contain a caution regarding abrupt cessation of the medicine due to the risk of serious side effects. The product labeling advises that any discontinuation, especially after long-term use, should be a gradual process managed under professional guidance.


Q: Can Lanzapine affect a person's ability to concentrate or remember things?

A: Official safety documents list somnolence (drowsiness) and trouble with thinking as potential side effects, which may lead to impaired concentration. Regulatory reports also list amnesia (memory impairment) as an uncommon adverse reaction.


Q: Why does the packaging of Lanzapine have so many warnings?

A: The large number of warnings is required by regulatory agencies because Lanzapine is classified as a powerful psychotropic agent. The detailed safety sections, including a Boxed Warning, are necessary to fully inform patients and professionals about the risk of serious adverse reactions associated with its use.


Q: Are there reports of Lanzapine causing vision changes or eye problems?

A: Official safety documents list several potential eye-related side effects. These include abnormal vision and blurred vision. In rare instances, involuntary eye movements (oculogyration) or difficulty focusing (accommodation abnormality) have been reported.


Q: Can men and women experience different side effects from Lanzapine?

A: Official documents note that the medicine's clearance from the body has been observed to be lower in females compared to males. Furthermore, specific side effects, such as elevated prolactin levels, are documented and can have different clinical manifestations in men and women.


Q: What is the connection between Lanzapine and feeling dizzy or light-headed?

A: Feeling dizzy or light-headed is primarily linked to the common side effect known as orthostatic hypotension. This occurs when a person feels dizzy upon standing up quickly, as the medicine can affect blood pressure regulation.


Q: Does Lanzapine change how other prescription medicines work in your body?

A: Official documents focus on how other medicines, especially those metabolized by the CYP1A2 enzyme, can change Lanzapine's concentration. The documents do not broadly describe Lanzapine changing the concentration or action of a wide range of other prescription medicines in the patient's body.


Q: Do people who take Lanzapine need special monitoring or blood tests?

A: Yes, regulatory guidelines require monitoring of several key health factors. This includes regular checks of weight, fasting blood glucose (blood sugar), and lipid profiles (cholesterol and triglycerides) at the start of treatment and periodically thereafter.

How should Lanzapine be stored and disposed of?

The storage and disposal of Lanzapine (Olanzapine) must strictly follow the requirements documented in official regulatory labeling to maintain the medicine's integrity.

Storage Conditions

Requirement Area Official Conditions
Temperature Store at room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C (86 F).
Protection Must be protected from light and moisture and kept in the original container.
Child Safety Store the medication out of the sight and reach of children.

Disposal Instructions

Official disposal mandates that unused or expired Lanzapine must not be thrown into household trash or flushed down the toilet. All product waste must be disposed of in accordance with local requirements for pharmaceutical waste. Used needles and syringes from the injectable formulation require specific disposal procedures by healthcare professionals.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanzapine found in:

A-Z Index: